Medios AG has appointed Stefan Bauerreis as a member of the Executive Board and as the Company's new Chief Financial Officer, effective April 15, 2026. He succeeds Falk Neukirch, who will step down at his own request at the end of his regular term of office on April 30, 2026. This leadership transition comes as Medios continues to position itself as Germany's first listed specialty pharmaceutical company, with shares traded on the regulated market of the Frankfurt Stock Exchange and included in the SDAX selection index.
With the appointment of Stefan Bauerreis, Medios gains an experienced finance expert with many years of international leadership experience in industry and at publicly traded companies. His background includes serving as Chief Financial Officer of the Stabilus Group and holding various senior finance positions within the Schaeffler Group for more than two decades, including as CFO for the Europe region and CFO for Germany. Bauerreis possesses extensive expertise in Corporate Accounting, Controlling, Financing, and the transformation and management of international companies.
Dr. Yann Samson, Chairman of the Supervisory Board of Medios AG, emphasized the strategic importance of this appointment, stating that with Stefan Bauerreis, the company is gaining a proven financial expert with extensive experience in internationally positioned SDAX and MDAX companies. Samson noted that Bauerreis combines operational excellence with strategic foresight and has repeatedly demonstrated throughout his career that he can successfully lead companies through periods of transformation. The Supervisory Board is convinced that he will provide important momentum for the future development of Medios.
Stefan Bauerreis expressed enthusiasm for his new role, stating that he looks forward to helping shape the future of Medios AG as part of the Executive Board. As CFO, he will contribute to further expanding the success of the Medios Group and its position as a leading Specialty Pharma company, both nationally and internationally, in the best interest of shareholders and employees. This appointment comes as Medios continues to focus on pioneering individualized medicine to make the most innovative therapies available to everyone together with pharmacies, specialist practices and pharmaceutical companies.
The leadership change occurs during a significant year for Medios, with several important events scheduled throughout 2026. These include the Metzler Small Cap Days in Frankfurt on April 15, the TP ICAP Midcap Conference in Paris on May 6, the Quarterly Statement as of March 31 on May 12, the Annual General Meeting on June 10, the Half-Year Financial Report on August 12, the Medios Capital Markets Day on September 28-29, and the Quarterly Statement as of September 30 on November 10. These events provide opportunities for the company to communicate its strategic direction under new financial leadership.
Medios operates as a leading provider of Specialty Pharma in Europe, with locations in Germany, the Netherlands, Belgium and Spain. The Company supports key partners in the supply chain with innovative solutions and intelligent services. More information about the company's approach to individualized medicine can be found at https://app.medios.group/en/individualizedmedicine. Additional company information is available at https://www.medios.group.
The appointment of an experienced CFO with international credentials signals Medios's commitment to strengthening its financial leadership as it continues to expand its European operations. For investors and industry observers, this leadership transition represents a strategic move to bring seasoned financial expertise to support the company's growth ambitions in the competitive specialty pharmaceutical sector. The timing of this appointment, just before several key financial reporting events, suggests the company is positioning itself for transparent communication and strategic financial management throughout 2026.
